Scientists have discovered a new way to advance drug discovery and diagnostics by targeting a part of the proteome (the complete set of proteins in an organism) that was previously thought ...

Beyond Serendipity: Redefining Rational Molecular Glue Discovery via AI-driven methodologies As a new generation of ...

For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...

Molly Gibson, PhD, has focused her attention on building companies at the intersection of AI and life sciences for the past decade, having co-founded both Generate: Biomedicines and Lila Sciences.

BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome ...

Parabilis raised $670M via 33.5M shares at $20 and secured $75M Regeneron private placement at $18, totaling ~$745M gross proceeds ahead of Nasdaq listing. Helicon discovery platform engineers ...

The reduction of α-synuclein, which is central to the pathogenesis of Parkinson’s disease and other α-synucleinopathies, can be accomplished through the binding and selective degradation of its ...

The term 'undruggable' refers to proteins or targets that are challenging to target with conventional drugs. In recent years, researchers have made progress in developing drugs that can interact with ...